Neuroendocrine TumorSymptoms, Doctors, Treatments, Advances & More
Learn About Neuroendocrine Tumor
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Duke Cancer Center
Diane Reidy is a Hematologist Oncology specialist and a Hematologist practicing medicine in Durham, North Carolina. Dr. Reidy is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.
Shishir Maithel is a Surgical Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 26 years. Dr. Maithel is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Hepatectomy. Dr. Maithel is board certified in American Board Of Surgery - Surgery (Certified).
Vanderbilt-Ingram Cancer Center
Kamran Idrees is a Colorectal Surgeon practicing medicine in Nashville, Tennessee. Dr. Idrees is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy.
Summary: The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with 2 other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how quickly their body gets rid of the drug; these people may do better with diffe...